Company Focus
Regeneron Pharmaceuticals Inc
Latest Regeneron Pharmaceuticals Inc News
Pharmaceutical
The atopic dermatitis market across the seven major markets is forecast to nearly triple in value over the next decade, driven by advances in targeted therapies and a deeper understanding of disease mechanisms. 5 June 2025
Related News
Insights
Company Spotlight
A biopharmaceutical company focused on developing tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.
Latest News & Features of interest to Regeneron Pharmaceuticals Inc
Pharmaceutical
US pharma major Bristol Myers Squibb has appointed Dr Nathan Pennell as senior vice president, worldwide head of medical affairs, hematology and oncology, effective August 18, 2025. 18 August 2025
Pharmaceutical
The European Commission (EC) granted marketing authorization for Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, as monotherapy for the treatment of adults with progressing desmoid tumors who require systemic treatment. 18 August 2025
Biotechnology
Boehringer Ingelheim and Palatin Technologies today announced a global research collaboration and licensing agreement aiming to develop an innovative therapy for retinal diseases. 18 August 2025
Biotechnology
The bladder cancer market across the eight major markets (8MM: USA, France, Germany, Italy, Spain, UK, China, and Japan) is projected to grow from $3 billion in 2023 to $16 billion in 2033, at a compound annual growth rate (CAGR) of 18%. 18 August 2025
Pharmaceutical
Japanese drugmaker Eisai today announced that its in-house-discovered and developed orexin receptor antagonist Dayvigo (brand name in China: “达卫可®“ generic name: lemborexant) has launched in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. 18 August 2025
Pharmaceutical
Australia’s Neurizon Therapeutics saw its shares rise 10% to A$0.16 today. after it revealed that it has been informed by the US Food and Drug Administration (FDA) that the decision on its Clinical Hold Complete Response (CHCR) to the Investigational New Drug (IND) application for NUZ-001, the company’s lead investigational therapy for amyotrophic lateral sclerosis (ALS), is now expected by October 3, 2025. 18 August 2025
Biotechnology
Pfizer reported that its Phase III THRIVE-131 study of inclacumab, an experimental P-selectin inhibitor for sickle cell disease, did not achieve its main goal of reducing vaso-occlusive crises. 18 August 2025
Pharmaceutical
AstraZeneca has launched FluMist Home, the first FDA-approved influenza vaccine program that allows self- or caregiver administration. FluMist (influenza vaccine live, intranasal) can now be delivered directly to households, making it the first seasonal flu shot available without a trip to the clinic or pharmacy. 18 August 2025
Pharmaceutical
Last week, PureTech Health spun out a new company, Celea Therapeutics, which will develop its pulmonary fibrosis candidate deupirfenidone (LYT-100). The US Food and Drug Administration (FDA) granted approval for Insmed’s Brinsupri (brensocatib) for the treatment of a chronic inflammatory lung condition. Last week also saw US biotech Sarepta Therapeutics selling 9.3 million shares in Arrowhead, raising around $174 million, and transferring around $50 million to Arrowhead. Basilea in-licensed rights to Venatorx’ urinary tract infection candidate ceftibuten-ledaborbactam etzadroxil. 17 August 2025
Pharmaceutical
The Swiss government has met with senior executives from Roche and Novartis to discuss the outlook for the pharmaceutical industry amid escalating US trade measures. 15 August 2025
Latest In Brief for Regeneron Pharmaceuticals Inc
Pharmaceutical
German family-owned pharma major Boehringer Ingelheim announced that Hernexeos (zongertinib tablets) has been recommended as a preferred subsequent therapy option for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with ERBB2 (HER2) mutations who received prior systemic therapy in the latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for non-small cell lung cancer (Version 8), updated on August 15, 2025 16 August 2025
Latest Relevant Ones To Watch News
Last week, PureTech Health spun out a new company, Celea Therapeutics, which will develop its pulmonary fibrosis candidate deupirfenidone (LYT-100). The US Food and Drug Administration (FDA) granted approval for Insmed’s Brinsupri (brensocatib) for the treatment of a chronic inflammatory lung condition. Last week also saw US biotech Sarepta Therapeutics selling 9.3 million shares in Arrowhead, raising around $174 million, and transferring around $50 million to Arrowhead. Basilea in-licensed rights to Venatorx’ urinary tract infection candidate ceftibuten-ledaborbactam etzadroxil. 17 August 2025
18 July 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze